Azienda Sanitaria Locale Napoli 1 Centro
- Address
- lock Available on a paid plan
Oncology and Digestive System Cancers
The oncology research at Azienda Sanitaria Locale Napoli 1 Centro focuses strongly on digestive system diseases, especially colorectal cancer and hepatocellular carcinoma. These studies are designed to compare treatment strategies, improve survival, and refine care for patients with advanced or metastatic disease.
- Metastatic colorectal cancer, including RAS/BRAF wild-type and liquid-biopsy-defined patient groups
- Intermediate-stage, locally advanced, and non-resectable hepatocellular carcinoma
- Advanced pancreatic cancer and treatment maintenance approaches
Several trials at the site evaluate whether newer immunotherapy combinations or targeted regimens can improve disease control and overall outcomes in difficult-to-treat gastrointestinal cancers.
Thoracic and Lung Cancer Research
The site also conducts important work in respiratory tract diseases, with a clear emphasis on non-small cell lung cancer. Research here is aimed at testing new treatment options after surgery and for more advanced disease, while also looking at ways to improve effectiveness in patients with uncommon genetic mutations.
- Advanced or metastatic non-squamous non-small cell lung cancer
- Early-stage non-squamous non-small cell lung cancer after resection
- Stage IB-IIIA NSCLC with uncommon EGFR mutations
These studies explore whether immunotherapy and targeted approaches can better support long-term cancer control and reduce recurrence risk.
Immune-Mediated Disease Studies
Beyond cancer, immune system diseases are an active area of investigation at this Naples site, particularly systemic lupus erythematosus. The trials are focused on understanding how to improve symptom control, response to therapy, and long-term safety for people living with chronic autoimmune disease.
- Systemic lupus erythematosus
- Evaluation of treatment response and sustained safety
- Studies comparing new immune-targeted therapies with standard care or placebo
These projects help clarify whether emerging therapies can offer more reliable disease control for patients with active autoimmune inflammation.
Brain and Rare Tumor Research
Research in neoplasms at the site includes studies in aggressive and rare tumors, with attention to improving outcomes where treatment options are limited. The main goal is to test whether new therapies can delay progression and support better disease management in both brain and solid tumors.
- Newly diagnosed glioblastoma
- Grade 1, 2, and 3 meningioma
- Solid tumours with specific biomarker features
These trials are designed to evaluate treatment effectiveness and help identify more promising options for patients with hard-to-treat cancers.
Head and Neck, Melanoma, and Biomarker-Driven Oncology
Another important research stream at P.O. Ospedale del Mare - UOC Oncologia involves head and neck cancer, melanoma, and biomarker-guided treatment selection. The studies aim to improve precision in cancer care by matching therapies more closely to tumor characteristics and disease spread.
- Squamous cell carcinoma of the head and neck
- Unresectable or metastatic melanoma
- Biomarker-informed treatment choices in advanced cancer
At this site, the research is centered on testing whether combination approaches can enhance tumor response and extend progression-free survival.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 35 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 13 by active trials.
lock +12 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.4trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Sanitaria Locale Napoli 1 Centro
lock Showing 1 of 25 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Comparative Study of ABP 234 and Pembrolizumab in Patients with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Amgen Inc. | Phase I | Recruiting | Oct 2024 | — |
IMP list
lock Showing 1 of 35 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Durvalumab | 5 | Unknown | 2021-10-20 | 2024-05-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.